As we approach the last of our exclusive coverage of ASCO 2023, editor-in-chief Jonah Comstock speaks with Mark Reisenauer, president of US commercial at Astellas.
Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer.
Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only ca
Astellas and Seagen's Padcev is on course to move further up the treatment pathway in bladder cancer, thanks to a positive readout in the EV-103 clinical trial.